eligibility_summary
Eligible: Stage IV squamous NSCLC, measurable disease, ECOG 0–1, tumor tissue, adequate organs, controlled HIV/HBV/HCV. Maintenance: no progression post‑induction. Exclude: small cell, severe ocular disease, IBD, major CV/cerebrovascular disease, CNS mets, active autoimmune disease, ILD or infection, prior metastatic systemic therapy or PD‑1/PD‑L1, TROP2/topo‑I ADC, recent/high‑dose lung RT, live vaccines, major surgery, strong CYP3A4 modulators, recent cancers, transplant, severe hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3, first-line metastatic squamous NSCLC. Induction: pembrolizumab + carboplatin + paclitaxel or nab‑paclitaxel, Maintenance: pembrolizumab with or without sacituzumab tirumotecan (sac‑TMT, MK‑2870). Mechanisms/types: Pembrolizumab—anti‑PD‑1 monoclonal antibody (immune checkpoint inhibitor) that blocks PD‑1 on T cells to restore antitumor immunity (PD‑1/PD‑L1 axis). Sac‑TMT—TROP2‑targeted antibody‑drug conjugate delivering a topoisomerase I inhibitor payload, binds TROP2 on tumor cells, internalizes, releases cytotoxic payload causing DNA damage. Carboplatin—platinum chemotherapy causing DNA crosslinks. Paclitaxel/nab‑paclitaxel—taxanes that stabilize microtubules and block mitosis. Targets/pathways: PD‑1 on T cells, TROP2 on tumor cells, DNA replication/topoisomerase I, DNA crosslink repair, microtubule/mitotic spindle.